Nintedanib Dose Modifications

Slides:

Advertisements

Similar presentations

TROPHY TRial Of Preventing HYpertension. High-normal BP increases CV risk Vasan RS et al. N Engl J Med. 2001;345: Incidence of CV events in women.

Advertisements

Hepatitis web study Hepatitis web study Telaprevir in Treatment Experienced GT-1 REALIZE (Study 216) Phase 3 Treatment Experienced Zeuzem S, et al. N Engl.

Weng TC, et al. J Clin Pharm Ther 2010;35:

Corticosteroid Randomisation After Significant Head Injury.

Interpreting INPULSIS® results Speaker: Luca Richeldi

Objective:To assess the effect of various clopidogrel and aspirin regimens on major CV events and ST in ACS patients undergoing PCI. Study:Multicenter,

Enrollment and Outcomes Fan Fan Hou, et al. N Engl J Med 2006;354:

Patient disposition Dichtl W, et al. Am J Cardiol. 2008;102:743-8 AVR = aortic valve replacement; MDCT = multidetector computed tomographic.

OFEV ® (nintedanib) safety Safety data INPULSIS ® -1 & -2 These slides are provided by Boehringer Ingelheim for medical to medical education only. Last.

INPULSIS® trial design and baseline characteristics

Baseline Patient Characteristics Bart A.N. Verhoeven, et al. Stroke 2006;37:

Hsia J et al. J Am Coll Cardiol 2011;57: Baseline Characteristics by Treatment Group and Attained LDL-C Hsia J et al. J Am Coll Cardiol 2011;57:

OFEV ® (nintedanib) TOMORROW trial results Last updated These slides are provided by Boehringer Ingelheim for medical to medical education only.

OFEV ® (nintedanib) efficacy INPULSIS ® trial results for acute IPF exacerbations Last updated These slides are provided by Boehringer Ingelheim.

PFF Teal = MAIN COLORS PFF Green = Light Green = Red = HIGHLIGHT COLORS Light Grey = Dark Grey =

Clinical Trials in IPF Dr Helen Parfrey. Are clinical trials needed ? Essential to determine if a drug therapy is beneficial Identify who will benefit.

Date of download: 7/9/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Around-the-Clock, Controlled-Release Oxycodone Therapy.

OFEV® (nintedanib) efficacy

Trial profile for the pharmacokinetics and pharmacodynamics study in patients with dyslipidaemia (A) and the ambulatory blood pressure study (B) *Participants.

Neal B, et al. Diabetes Care 2015;38:403–411

PFF Summit 2015 Highlights Washington, US references

Presented By Luca Malorni at 2017 ASCO Annual Meeting

IPF treatment with nintedanib

Daniel J. Lenihan et al. BTS 2016;1:

Early Clinical Experiences with Nintedanib in 3 Tertiary Interstitial Lung Disease Centres

Five Years of Real World Pirfenidone Experience

Filming: 15th of Febuary 2016, London, UK

Patient disposition for the double-blind study period.

Clinical Trial of Vadadustat in Patients with Anemia Secondary to Stage 3 or 4 Chronic Kidney Disease Martin et al. Am J Nephrol 2017;45: (DOI:

Key clinical efficacy outcomes for (A) hemoglobin A1c (HbA1c), (B) weight change. Key clinical efficacy outcomes for (A) hemoglobin A1c (HbA1c), (B) weight.

Real World Experiences: Pirfenidone is well tolerated and reduces decline in FVC and TLCO at 9 months in Idiopathic Pulmonary Fibrosis (IPF). Nazia Chaudhuri*,

Krop I et al. SABCS 2009;Abstract 5090.

Filming: 15th of Febuary 2016, London, UK

Demographics of IPF in the USa-d

Long-term Data: INPULSIS®-ON

A: Kaplan-Meier estimate of time to first LLA

Q.A. Truong et al. Circ Cardiovasc Qual Outcomes 2011;4:

Modelled mean (SEM) observed forced vital capacity (FVC) volume change from baseline (mL) over time by dose intensity (>90%, ≤90%), based on actual dose.

HARMONIZE Trial design: Patients with hyperkalemia (K ≥5.1 mEq/L) were randomized in a 1:1:1:1.7 fashion to receive sodium zirconium cyclosilicate (ZS)

CHAMPION Trial design: Patients with recent hospitalization for heart failure were implanted with a pulmonary artery pressure monitor and randomized so.

Flow of Patients Through the Trial

Flow of Patients Through Trial

Study Participant Flow

Flow Diagram of the Trial Selection Process

Patient disposition. Patient disposition. AE, adverse event. *One patient died during the follow-up period. ^Four of the 12 discontinuations of treatment.

Patient Disposition James A. de Lemos et al. JAMA 2004; 292:

Systems biology as a tool to improve idiopathic pulmonary fibrosis (IPF) treatment effectiveness. Systems biology as a tool to improve idiopathic pulmonary.

SOLID-TIMI 52 Trial design: Participants within 30 days of an acute coronary syndrome (ACS) were randomized to darapladib 160 mg daily (n = 6,504) versus.

Participation in Japanese Primary Prevention of Atherosclerosis With Aspirin for Diabetes (JPAD) Trial Hisao Ogawa et al. JAMA 2008;300:

Patients’ most feared AEs reported to be intolerable when lasting more than 7 days at baseline, on study and at study completion (% patients); (A) grade.

Telaprevir in Treatment Experienced GT-1 PROVE3

MATRIX: Radial vs. Femoral

Glenn N. Levine et al. JACC 2011;58:e44-e122

Difference in the risk of MACEs in patients treated with anti–IL17 agents compared with the placebo in RCTs. IL,interleukin; MACEs, major adverse cardiovascular.

New Models of Care in Idiopathic Pulmonary Fibrosis

Baseline demographics and clinical characteristics of 3,956 rosuvastatin-treated patients Donald G. Vidt, et al. Am J Cardiol 2006;97:1602–1606.

Difference in the risk of MACEs in patients treated with anti-IL23 agents compared with the placebo in RCTs. IL, interleukin; MACEs, major adverse cardiovascular.

Flow of study participants

Impact of dose adjustment in case of adverse drug reaction (ADR; includes dose interruption and/or reduction). a) No dose adjustment and b) dose adjustment.

Telaprevir + Peginterferon + Ribavirin for GT1 PROVE1 Study

Changes in glycated hemoglobin (HbA1c) levels after 12 weeks’ treatment with lixisenatide (according to dose increase regimen) or placebo. Changes in glycated.

Difference in the risk of MACEs in patients treated with anti-TNF agents compared with the placebo in RCTs. MACEs, major adverse cardiovascular events;

Number of patients treated at clinics that followed up fewer than 10 patients (2013–2016) or 20 patients (2012) and proportion of patients followed up.

Mean changes (standard error) from baseline in A1C (A and B) and body weight (C and D) for patients with type 1 (A and C) or type 2 (B and D) diabetes.

Risk ratio (RR) and number needed to treat (NNT) are time-dependent measures. a) When an intervention is associated with constant relative risk reduction.

Reduction in mean pulmonary vascular resistance (PVR) in 37 subjects following acute sildenafil administration to ongoing bosentan therapy in the COMPASS-1.

Change in FES uptake in the tumor during fulvestrant treatment.

The best response for target lesions per patient for patients with target lesions assessed at baseline and at least 1 follow-up. The best response for.

PHOENIX I: PASI 75 Response After 12 Weeks

Mean change from baseline in percentage predicted forced vital capacity (FVC) in the a) phase III CAPACITY [27] and b) ASCEND [14] studies. #: n=174; ¶:

Presentation transcript:

Nintedanib Dose Modifications Filming: 15th of Febuary 2016, London, UK Prof. Vincent Cottin Prof. Luca Richeldi

Nintedanib was effective even in patients with dose reductions and treatment interruptions Change from baseline in FVC in patients treated with nintedanib1 ≥1 dose reduction due to side effects ≥1 treatment interruption due to side effects These results indicate that the dosing regimen used in the INPULSIS® trials, which allowed for dose reductions and treatment interruptions to manage adverse events, was effective in patients with IPF. Yes (n=178) No (n=460) Yes (n=151) No (n=487) Absolute mean change from baseline in FVC (mL) 1. Richeldi L, et al. Poster presented at PFF Summit 2015. references